镥-177 (Lu-177) 前列腺特异性膜抗原 (PSMA) 疗法是一种针对晚期前列腺癌患者的核医学放射性核素靶向疗法。
Lu-177 PSMA 疗法可以对通常对放射敏感的前列腺癌细胞进行非常特异的靶向放射治疗。它通常用于转移性去势抵抗性前列腺癌。该疗法旨在缩小肿瘤并稳定疾病。
身体对其他疗法或治疗没有反应的患者可能会被转介接受这种疗法。
Despite both affecting the same gland and sharing similar symptoms, benign prostate hyperplasia (BPH) is a non-cancerous condition that results in an enlarged prostate. It is not known to lead to prostate cancer.
Click to learn more about BPH and prostate cancer.